Plexus Ventures
Plexus
We help companies identify, evaluate, and negotiate in-licensing opportunities to expand their growth potential and geographic presence.
We advise companies in developing an out-licensing strategy and guide them in maximizing the value of their compounds, products, and technologies.
We help firms identify potential product and company acquisitions, develop deal structures, and negotiate definitive agreements.
We are global experts in pharmaceutical divestments, working with companies to target buyers, generate competition for assets, and maximize proceeds.
GLOBAL PRESENCE world

1-888-PLEXUS0 (753-9870)

info@plexusventures.com
RECENT NEWS
  • December 11, 2008 Plexus Ventures Signs Three New Clients; Undertakes Diverse Out-licensing Assignments
  • October 23, 2008 Plexus Ventures Assists GlaxoSmithKline to Divest Oral Healthcare Product
  • October 22, 2008 Plexus Ventures Continues Geographic Expansion with Addition of Two Senior Consultants
  • May 21, 2008 Plexus Ventures to Provide Business Development Support to US Pharmacia
PharmaTimes World News
  • December 23, 2008AstraZeneca links up with Biocompatibles for GLP-1 drug
  • December 23, 2008Ranbaxy to pay £1 million to settle Scottish “cartel” case
  • December 22, 2008NHS to be £13 million off budget by 2013 - Monitor's forecast
  • December 23, 2008Antisoma looks for partner for US-approved oral fludarabine
  • December 23, 2008MHRA consults on proposals to battle counterfeit drugs
Home | About | Services | Track Record | News Room | Contact | Japanese Japanese Language
  • Overview
  • Our Approach
  • Our History
  • Our Team
  • Our Offices
  • Overview
  • In-Licensing
  • Out-Licensing
  • Acquisitions
  • Divestments
  • Overview
  • Case Studies
  • Client List
  • Press Releases
  • Articles & Presentations
  • Media Inquiries